Table 3.

Base-case analyses: high-dose vs. no treatment, and standard dose vs. no treatment

						Payer perspective		Societal perspective
Comparators	Δ Costsa (payer)	Δ Costsa (societal)	Δ Death	Δ LYs	Δ QALYs	Cost per LY gained	Cost per QALY gained	Cost per LY gained	Cost per QALY gained
Low virulence and low transmissibility
75 mg vs. no treatment
25% uptake	−30 246 490	−81 272 885	−706	335	361	Cost-saving	Cost-saving	Cost-saving	Cost-saving
50% uptake	−33 352 767	−93 996 756	−412	399	430	Cost-saving	Cost-saving	Cost-saving	Cost-saving
80% uptake	−30 406 894	−92 614 326	−783	410	441	Cost-saving	Cost-saving	Cost-saving	Cost-saving
150 mg vs. no treatment
25% uptake	−29 839 058	−85 192 106	−376	364	392	Cost-saving	Cost-saving	Cost-saving	Cost-saving
50% uptake	−27 742 305	−89 785 170	−423	409	441	Cost-saving	Cost-saving	Cost-saving	Cost-saving
80% uptake	−20 483 671	−83 687 273	−430	416	449	Cost-saving	Cost-saving	Cost-saving	Cost-saving
150 vs. 75 mg
25% uptake	407 432	−3 919 221	−30	29	31	14 018	13 117	Cost-saving	Cost-saving
50% uptake	5 610 462	4 110 702	−11	10	11	546 753	515 260	400 598	377 524
80% uptake	9 923 223	8 927 052	−7	7	7	1 423 516	1 353 188	1 280 612	1 217 344
High virulence and high transmissibility
75 mg vs. no treatment
25% uptake	−11 885 337	−27 413 072	−168	162	174	Cost-saving	Cost-saving	Cost-saving	Cost-saving
50% uptake	−49 309 677	−101 904 191	−617	598	629	Cost-saving	Cost-saving	Cost-saving	Cost-saving
80% uptake	−88 899 525	−179 850 525	−1098	1063	1112	Cost-saving	Cost-saving	Cost-saving	Cost-saving
150 mg vs. no treatment
25% uptake	−24 304 917	−53 631 551	−341	331	349	Cost-saving	Cost-saving	Cost-saving	Cost-saving
50% uptake	−63 252 396	−133 577 886	−844	818	856	Cost-saving	Cost-saving	Cost-saving	Cost-saving
80% uptake	−95 501 955	−200 976 888	−1288	1247	1302	Cost-saving	Cost-saving	Cost-saving	Cost-saving
150 vs. 75 mg
25% uptake	−12 419 581	−26 218 479	−174	168	174	Cost-saving	Cost-saving	Cost-saving	Cost-saving
50% uptake	−13 942 719	−31 673 695	−227	220	227	Cost-saving	Cost-saving	Cost-saving	Cost-saving
80% uptake	−6 602 430	−21 126 363	−190	184	189	Cost-saving	Cost-saving	Cost-saving	Cost-saving

^aAll costs are expressed in 2013 USD.